In a historic move, French Health Minister Stéphanie Rist announced that France will begin reimbursing the costs of weight loss medications such as 'Wegovy' and 'Monjaro' starting June 15. This step makes France the first country in the European Union to cover the costs of these medications, reflecting the French government's commitment to enhancing the health of its citizens.
Rist expressed pride in this achievement, stating that "France is the first country in the EU to provide reimbursement under standard coverage, permanently." She explained that the official coverage rate will reach 65%, but most patients will receive full coverage due to accompanying medical conditions such as hypertension or diabetes, meaning that the vast majority will benefit from coverage up to 100%.
Details of the Announcement
The medications 'Wegovy', produced by Novo Nordisk from Denmark, and 'Monjaro' from Eli Lilly, are part of a new generation of weight loss drugs. These medications work by mimicking a hormone that reduces appetite, helping individuals lose weight more effectively. According to estimates, there were over 70,000 patients receiving 'Monjaro' treatment in France by the end of January.
Although these treatments have been available in France by prescription since 2024, they had not been approved for reimbursement by the national health insurance system until now. In June 2025, all doctors, not just specialists like endocrinologists, will be allowed to prescribe these medications to patients.
Background & Context
Statistics indicate that approximately 18% of the French population, or nearly 10 million people, suffer from obesity. In the European Union, it is estimated that 51% of the population aged 16 and above are overweight, with 17% of them classified as obese, according to data from the European Parliament. These figures reflect a growing health crisis that requires an effective response from governments.
Historically, weight loss medications have faced significant accessibility challenges due to their high costs, with patients in France paying around €300 per month for injections. However, the French government's decision to cover the costs of these medications represents a positive step towards improving access to effective treatments.
Impact & Consequences
This decision is expected to have a significant impact on public health in France, as it will help reduce obesity rates and associated diseases. It also reflects a shift in health policies towards supporting treatments that enhance quality of life.
Furthermore, this decision may encourage other countries in the European Union to take similar steps, leading to improved access to health treatments across the continent. Enhancing public health can also lead to reduced healthcare costs in the long term.
Regional Significance
In the Arab region, obesity and weight gain are increasingly pressing health issues. Although Arab countries have not yet taken similar steps, France's experience may inspire some Arab nations to consider similar policies to improve the health of their citizens. Addressing obesity issues can contribute to enhancing quality of life and reducing chronic diseases.
In conclusion, France's decision to cover the costs of weight loss medications represents a pioneering step in public health, and it may have positive effects on public health in Europe and beyond.